Research ArticleArticle
Immunoglobulin G Subclass Analysis in Psoriatic Arthritis
Amir Haddad, Arane Thavaneswaran, Fatima Abji, Fawnda Pellett, Vinod Chandran, Joan E. Wither and Dafna D. Gladman
The Journal of Rheumatology October 2014, jrheum.131477; DOI: https://doi.org/10.3899/jrheum.131477
Amir Haddad
From the Division of Rheumatology, Department of Medicine, University of Toronto Psoriatic Arthritis Program, and the Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. The Psoriatic Arthritis Program is funded in part by The Arthritis Society, Canadian Institutes of Health Research, and the Krembil Foundation. Dr. Haddad was supported by fellowship grants from the Krembil Foundation and UCB. A. Haddad, MD, Clinical Research Fellow; A. Thavaneswaran, MMath, Biostatistician; F. Abji, MSc; F. Pellett, BSc; V. Chandran, MBBS, MD, DM, PhD, Assistant Professor of Medicine; J.E. Wither, MD, PhD, FRCPC, Professor of Medicine and Immunology; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Department of Medicine, Division of Rheumatology, and Director, University of Toronto Psoriatic Arthritis Program, and Deputy Director, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital. Address correspondence to Dr. D.D. Gladman, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst St., 1E-410B, Toronto, Ontario M5T 2S8, Canada. E-mail: dafna.gladman@utoronto.ca. Accepted for publication August 6, 2014.
Arane Thavaneswaran
From the Division of Rheumatology, Department of Medicine, University of Toronto Psoriatic Arthritis Program, and the Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. The Psoriatic Arthritis Program is funded in part by The Arthritis Society, Canadian Institutes of Health Research, and the Krembil Foundation. Dr. Haddad was supported by fellowship grants from the Krembil Foundation and UCB. A. Haddad, MD, Clinical Research Fellow; A. Thavaneswaran, MMath, Biostatistician; F. Abji, MSc; F. Pellett, BSc; V. Chandran, MBBS, MD, DM, PhD, Assistant Professor of Medicine; J.E. Wither, MD, PhD, FRCPC, Professor of Medicine and Immunology; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Department of Medicine, Division of Rheumatology, and Director, University of Toronto Psoriatic Arthritis Program, and Deputy Director, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital. Address correspondence to Dr. D.D. Gladman, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst St., 1E-410B, Toronto, Ontario M5T 2S8, Canada. E-mail: dafna.gladman@utoronto.ca. Accepted for publication August 6, 2014.
Fatima Abji
From the Division of Rheumatology, Department of Medicine, University of Toronto Psoriatic Arthritis Program, and the Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. The Psoriatic Arthritis Program is funded in part by The Arthritis Society, Canadian Institutes of Health Research, and the Krembil Foundation. Dr. Haddad was supported by fellowship grants from the Krembil Foundation and UCB. A. Haddad, MD, Clinical Research Fellow; A. Thavaneswaran, MMath, Biostatistician; F. Abji, MSc; F. Pellett, BSc; V. Chandran, MBBS, MD, DM, PhD, Assistant Professor of Medicine; J.E. Wither, MD, PhD, FRCPC, Professor of Medicine and Immunology; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Department of Medicine, Division of Rheumatology, and Director, University of Toronto Psoriatic Arthritis Program, and Deputy Director, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital. Address correspondence to Dr. D.D. Gladman, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst St., 1E-410B, Toronto, Ontario M5T 2S8, Canada. E-mail: dafna.gladman@utoronto.ca. Accepted for publication August 6, 2014.
Fawnda Pellett
From the Division of Rheumatology, Department of Medicine, University of Toronto Psoriatic Arthritis Program, and the Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. The Psoriatic Arthritis Program is funded in part by The Arthritis Society, Canadian Institutes of Health Research, and the Krembil Foundation. Dr. Haddad was supported by fellowship grants from the Krembil Foundation and UCB. A. Haddad, MD, Clinical Research Fellow; A. Thavaneswaran, MMath, Biostatistician; F. Abji, MSc; F. Pellett, BSc; V. Chandran, MBBS, MD, DM, PhD, Assistant Professor of Medicine; J.E. Wither, MD, PhD, FRCPC, Professor of Medicine and Immunology; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Department of Medicine, Division of Rheumatology, and Director, University of Toronto Psoriatic Arthritis Program, and Deputy Director, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital. Address correspondence to Dr. D.D. Gladman, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst St., 1E-410B, Toronto, Ontario M5T 2S8, Canada. E-mail: dafna.gladman@utoronto.ca. Accepted for publication August 6, 2014.
Vinod Chandran
From the Division of Rheumatology, Department of Medicine, University of Toronto Psoriatic Arthritis Program, and the Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. The Psoriatic Arthritis Program is funded in part by The Arthritis Society, Canadian Institutes of Health Research, and the Krembil Foundation. Dr. Haddad was supported by fellowship grants from the Krembil Foundation and UCB. A. Haddad, MD, Clinical Research Fellow; A. Thavaneswaran, MMath, Biostatistician; F. Abji, MSc; F. Pellett, BSc; V. Chandran, MBBS, MD, DM, PhD, Assistant Professor of Medicine; J.E. Wither, MD, PhD, FRCPC, Professor of Medicine and Immunology; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Department of Medicine, Division of Rheumatology, and Director, University of Toronto Psoriatic Arthritis Program, and Deputy Director, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital. Address correspondence to Dr. D.D. Gladman, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst St., 1E-410B, Toronto, Ontario M5T 2S8, Canada. E-mail: dafna.gladman@utoronto.ca. Accepted for publication August 6, 2014.
Joan E. Wither
From the Division of Rheumatology, Department of Medicine, University of Toronto Psoriatic Arthritis Program, and the Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. The Psoriatic Arthritis Program is funded in part by The Arthritis Society, Canadian Institutes of Health Research, and the Krembil Foundation. Dr. Haddad was supported by fellowship grants from the Krembil Foundation and UCB. A. Haddad, MD, Clinical Research Fellow; A. Thavaneswaran, MMath, Biostatistician; F. Abji, MSc; F. Pellett, BSc; V. Chandran, MBBS, MD, DM, PhD, Assistant Professor of Medicine; J.E. Wither, MD, PhD, FRCPC, Professor of Medicine and Immunology; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Department of Medicine, Division of Rheumatology, and Director, University of Toronto Psoriatic Arthritis Program, and Deputy Director, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital. Address correspondence to Dr. D.D. Gladman, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst St., 1E-410B, Toronto, Ontario M5T 2S8, Canada. E-mail: dafna.gladman@utoronto.ca. Accepted for publication August 6, 2014.
Dafna D. Gladman
From the Division of Rheumatology, Department of Medicine, University of Toronto Psoriatic Arthritis Program, and the Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. The Psoriatic Arthritis Program is funded in part by The Arthritis Society, Canadian Institutes of Health Research, and the Krembil Foundation. Dr. Haddad was supported by fellowship grants from the Krembil Foundation and UCB. A. Haddad, MD, Clinical Research Fellow; A. Thavaneswaran, MMath, Biostatistician; F. Abji, MSc; F. Pellett, BSc; V. Chandran, MBBS, MD, DM, PhD, Assistant Professor of Medicine; J.E. Wither, MD, PhD, FRCPC, Professor of Medicine and Immunology; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Department of Medicine, Division of Rheumatology, and Director, University of Toronto Psoriatic Arthritis Program, and Deputy Director, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital. Address correspondence to Dr. D.D. Gladman, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst St., 1E-410B, Toronto, Ontario M5T 2S8, Canada. E-mail: dafna.gladman@utoronto.ca. Accepted for publication August 6, 2014.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Immunoglobulin G Subclass Analysis in Psoriatic Arthritis
Amir Haddad, Arane Thavaneswaran, Fatima Abji, Fawnda Pellett, Vinod Chandran, Joan E. Wither, Dafna D. Gladman
The Journal of Rheumatology Oct 2014, jrheum.131477; DOI: 10.3899/jrheum.131477